Key Points
- Christina Rizopoulos Valauri, a director, bought 19,000 shares on April 1 at an average price of $0.95 per share for a total of $18,050 and now directly owns 19,000 shares.
- Tivic Health is a micro‑cap (market cap $1.77M) medical‑device company that reported ($1.03) EPS for the quarter and shows very weak profitability (ROE -202.20%, net margin -1,557.26%).
- Marex Group plc bought 39,283 shares (~$163,000) to hold about 3.64% of the company, yet analyst sentiment remains negative with Weiss Ratings reiterating a "Sell" and an average rating of "Sell".
Tivic Health Systems, Inc. (NASDAQ:TIVC - Get Free Report) Director Christina Rizopoulos Valauri bought 19,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was purchased at an average price of $0.95 per share, with a total value of $18,050.00. Following the purchase, the director directly owned 19,000 shares of the company's stock, valued at $18,050. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Tivic Health Systems Price Performance
Shares of TIVC opened at $1.00 on Friday. The company has a market capitalization of $1.77 million, a P/E ratio of -0.15 and a beta of 1.84. Tivic Health Systems, Inc. has a one year low of $0.72 and a one year high of $13.23. The business's 50 day simple moving average is $0.93 and its 200-day simple moving average is $1.76.
Tivic Health Systems (NASDAQ:TIVC - Get Free Report) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($408.00) by $406.97. Tivic Health Systems had a negative return on equity of 202.20% and a negative net margin of 1,557.26%.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Tivic Health Systems in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of "Sell".
Get Our Latest Stock Report on Tivic Health Systems
Institutional Investors Weigh In On Tivic Health Systems
A hedge fund recently bought a new stake in Tivic Health Systems stock. Marex Group plc bought a new position in Tivic Health Systems, Inc. (NASDAQ:TIVC - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 39,283 shares of the company's stock, valued at approximately $163,000. Marex Group plc owned 3.64% of Tivic Health Systems as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 4.25% of the company's stock.
About Tivic Health Systems
(
Get Free Report)
Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company's solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.
The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
